Efficacy and Safety of Valsartan Versus Amlodipine in Postmenopausal Women With Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Hypertension
Interventions
DRUG

Valsartan 320 mg

Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.

DRUG

Amlodipine 10 mg

Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.

DRUG

Hydrochlorothiazide

At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure \< 140 mmHg and Diastolic Blood Pressure \< 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.

Trial Locations (1)

Unknown

Novartis Pharmaceuticals, Basel

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY